Daxor Corporation (DXR)
8.43
0.13 (1.57%)
At close: Jan 14, 2025, 1:30 PM
8.43
0.00%
After-hours Jan 14, 2025, 01:30 PM EST
undefined% (undefined)
| Bid | 7.55 |
| Market Cap | 40.78M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.16 |
| PE Ratio (ttm) | 7.27 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 9.32 |
| Volume | 1,850 |
| Avg. Volume (20D) | 17,386 |
| Open | 7.92 |
| Previous Close | 8.30 |
| Day's Range | 7.92 - 8.43 |
| 52-Week Range | 7.19 - 10.03 |
| Beta | undefined |
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Jul 25, 1983
Employees 37
Stock Exchange NASDAQ
Ticker Symbol DXR
Website https://www.daxor.com
Analyst Forecast
According to 1 analyst ratings, the average rating for DXR stock is "Strong Buy." The 12-month stock price forecast is $24.75, which is an increase of 193.59% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
9 months ago · seekingalpha.com
Daxor Corporation (DXR) Q4 2023 Earnings Call TranscriptDaxor Corporation (DXR) Q4 2023 Earnings Call Transcript
